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Background:  Cardiac fibrosis is attributed to excess deposition of extracellular matrix components pathologically. The mechanism remains 
unclear, however recent reports say myofibroblasts are primarily responsible for fibrosis. Myofibroblasts are differentiated from resident fibroblasts 
and circulating fibrocytes, while vascular endothelial cells can be transformed into myofibroblasts, known as End-MT (Endothelial-Mesenchymal 
Transition), which is intimately associated with perivascular fibrosis. Out of these findings, we hypothesized that HGF (hepatocyte growth factor) 
contributes to prevent cardiac fibrosis through suppressing End-MT and proliferation of myofibroblast. 
Methods:  In vitro HCAECs (human coronary artery endothelial cells) were divided in 4 groups except control; treated with 1ng/ml, 10ng/ml 
TGF-`1 with and without 50ng/ml HGF. _-SMA (smooth muscle actin) and collagenI expression were measured by quantitative PCR after 7 days. 
HCFs (human cardiac fibroblasts) were stimulated with 10-6M AngII added 50ng/ml HGF after 24 hours interval and performed proliferation assay 
as well as _-SMA measurement by Western blot analysis. In vivo we analyzed pressure overloaded HGF-transgenic mouse model made by transverse 
aortic constriction.
Results:  HGF inhibited differentiation of HCAECs into myofibroblasts induced by TGF-`1 stimulation in vitro. Proliferation assay showed 31% 
suppression in number of myofibroblasts differentiated from AngII pretreatmented HCFs. In vivo study, mRNA expression of collagen I/III and TGF-`1 
was significantly lower than that of non-Tg group 14 days after surgery. Fibrotic area was approximately half the size in operated HGF-Tg mice in 
perivascular region accompanied by the reduction of myofibroblasts. In echocardiography, both FS (WT 28.1±1.3 vs. Tg 37.7±2.3%, P<0.05) and 
LVDD were preserved compared with banded littermates and survival rate 2 months after operation was higher by 45% as well.
Conclusions:  We concluded HGF reduces cardiac fibrosis through inhibiting End-MT and myofibroblast proliferation. These findings suggest a 
therapeutic target to preserve cardiac performance of failing heart due to chronic pressure overload.
